company background image
AVIR

Atea Pharmaceuticals NasdaqGS:AVIR Stock Report

Last Price

US$4.69

Market Cap

US$390.6m

7D

0.4%

1Y

-42.4%

Updated

27 Nov, 2022

Data

Company Financials +
AVIR fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance4/6
Financial Health6/6
Dividends0/6

AVIR Stock Overview

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections.

Atea Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Atea Pharmaceuticals
Historical stock prices
Current Share PriceUS$4.69
52 Week HighUS$9.79
52 Week LowUS$4.45
Beta0.37
1 Month Change-17.14%
3 Month Change-40.10%
1 Year Change-42.38%
3 Year Changen/a
5 Year Changen/a
Change since IPO-84.54%

Recent News & Updates

Atea wins FDA Fast Track status for dengue treatment

Sep 26

Recent updates

Atea Pharmaceuticals, Inc.'s (NASDAQ:AVIR) Shares Not Telling The Full Story

May 13
Atea Pharmaceuticals, Inc.'s (NASDAQ:AVIR) Shares Not Telling The Full Story

Analysts Just Shaved Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Forecasts Dramatically

Jan 05
Analysts Just Shaved Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Forecasts Dramatically

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Analysts Just Slashed Next Year's Estimates

Nov 25
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Analysts Just Slashed Next Year's Estimates

A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)

Oct 24
A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)

A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)

Oct 24
A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)

Atea Pharmaceuticals, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates

May 15
Atea Pharmaceuticals, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates

Market Sentiment Around Loss-Making Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)

May 13
Market Sentiment Around Loss-Making Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)

Growth Investors: Industry Analysts Just Upgraded Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Revenue Forecasts By 73%

Apr 08
Growth Investors: Industry Analysts Just Upgraded Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Revenue Forecasts By 73%

Atea Pharmaceuticals (NASDAQ:AVIR) Is In A Strong Position To Grow Its Business

Mar 06
Atea Pharmaceuticals (NASDAQ:AVIR) Is In A Strong Position To Grow Its Business

Need To Know: Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Insiders Have Been Buying Shares

Jan 30
Need To Know: Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Insiders Have Been Buying Shares

Shareholder Returns

AVIRUS PharmaceuticalsUS Market
7D0.4%1.6%1.3%
1Y-42.4%9.9%-18.5%

Return vs Industry: AVIR underperformed the US Pharmaceuticals industry which returned 9.9% over the past year.

Return vs Market: AVIR underperformed the US Market which returned -18.5% over the past year.

Price Volatility

Is AVIR's price volatile compared to industry and market?
AVIR volatility
AVIR Average Weekly Movement8.0%
Pharmaceuticals Industry Average Movement11.0%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: AVIR is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: AVIR's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201268Jean-Pierre Sommadossihttps://ateapharma.com

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection.

Atea Pharmaceuticals, Inc. Fundamentals Summary

How do Atea Pharmaceuticals's earnings and revenue compare to its market cap?
AVIR fundamental statistics
Market CapUS$390.62m
Earnings (TTM)US$35.65m
Revenue (TTM)US$192.18m

11.0x

P/E Ratio

2.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AVIR income statement (TTM)
RevenueUS$192.18m
Cost of RevenueUS$112.21m
Gross ProfitUS$79.97m
Other ExpensesUS$44.32m
EarningsUS$35.65m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.43
Gross Margin41.61%
Net Profit Margin18.55%
Debt/Equity Ratio0%

How did AVIR perform over the long term?

See historical performance and comparison